Wegovy is the semaglutide brand used for weight management and, in some circumstances, cardiovascular risk reduction
Because it is an injection, it should always be given by a trained provider, and we start every patient with a consultation and testing to confirm the treatment is right for them
This is not required for safety but smooths the transition
Oxygen sensing and metabolic homeostasis
GLP-1 RAs have been shown to reduce the risk of major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death
Pan D, Vargas-Morales O, Zern B et al (2016) The effect of polymeric nanoparticles on biocompatibility of carrier red blood cells